Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
14 Jan 2008 King Pharmaceuticals Reports FDA Approval Of Revised Labeling Regarding Purity Of THROMBIN-JMI(R)
14 Jan 2008 Three Rivers Pharmaceuticals®, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
13 Jan 2008 New published data show otoprotective effect of AM-111 in case of inner ear inflammatory responses (acute labyrinthitis)
11 Jan 2008 Jerini Announces Collaboration Agreement with Baxter to Develop Novel Peptide for Use in Therapeutic Protein Purification
11 Jan 2008 LFB Biotechnologies to Collaborate With GTC Biotherapeutics on Coagulation Factor IX Program
10 Jan 2008 Allon trial studies pharmacokinetics of AL-108 & AL-208
10 Jan 2008 OMRIX Biopharmaceuticals Receives FDA Approval for General Hemostasis in Surgery Indication for EVICEL(TM) Liquid Fibrin Sealant (Human)
09 Jan 2008 ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined with Nexavar(R)
08 Jan 2008 Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
08 Jan 2008 Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
08 Jan 2008 Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
07 Jan 2008 Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
07 Jan 2008 Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
07 Jan 2008 Catalyst Biosciences and Centocor Research & Development, inc. fForm collaboration to discover and develop engineered protease therapeutics
07 Jan 2008 Baxter Announces Recombinant Factor IX Development Program for Hemophilia B
03 Jan 2008 Protox announces positive final results from BPH study
21 Dec 2007 Lundbeck expands agreement with PAION for desmoteplase
21 Dec 2007 Pfizer Receives Approvable Letter from FDA for Dalbavancin
21 Dec 2007 Pharming Submits Request For Re-examination Of CHMP Opinion For European Marketing Authorization Application For Rhucin(R)
21 Dec 2007 Jerini Receives NDA Filing Acceptance and Priority Review from the FDA for Icatibant in the Treatment of HAE
21 Dec 2007 ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
20 Dec 2007 Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
20 Dec 2007 Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
19 Dec 2007 BioLineRx Announces Presentation of Pre-Clinical Data Demonstrating that BL-2030 Reduces Tumor Growth and Prevents Metastasis in Model of Prostate Cancer
19 Dec 2007 Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialzation Rights
18 Dec 2007 ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma
18 Dec 2007 Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
17 Dec 2007 Novo Nordisk licenses global rights to potential new haemostasis therapy
14 Dec 2007 Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation
13 Dec 2007 Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
13 Dec 2007 Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11 Dec 2007 Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight
11 Dec 2007 ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
11 Dec 2007 Medicis and Revance Announce Strategic Collaboration
10 Dec 2007 ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma
10 Dec 2007 CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10 Dec 2007 Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting
09 Dec 2007 Nuvelo Phase 3 SONOMA-2 Trial Shows Alfimeprase has the Potential to Restore Catheter Function
08 Dec 2007 Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
07 Dec 2007 Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
07 Dec 2007 Submission of Marketing Authorisation Application for Dapoxetine in Europe
07 Dec 2007 Access Pharmaceuticals Demonstrates Ability To Significantly Reduce Glucose Levels in Pre-clinical Testing of
06 Dec 2007 Ipsen submits a Biologics License Application (BLA) in cervical dystonia to the FDA for Dysport(R)
06 Dec 2007 Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA
05 Dec 2007 Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
05 Dec 2007 GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
04 Dec 2007 ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
03 Dec 2007 Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study
03 Dec 2007 Fibrex Medical Completes Enrolment of Phase II Trial of Treatment for
03 Dec 2007 Clal Biotechnology Industries and Teva Pharmaceuticals Solidify their Collaboration for Final Stage Development of Type 1 Diabetes Drug
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 401 - 450 of 1429

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics